Abstracts Archive - Page 948 of 2425 - ACR Meeting Abstracts

Abstract Number: 2848 • 2019 ACR/ARP Annual Meeting
Semiquantitative Assessment of Synovial Inflammation on US-Guided Synovial Membrane Biopsy Is Contingent to Disease Phase, Autoimmune Profile and Treatment Response in Rheumatoid Arthritis: Large Single Center Experience (SYNGem Cohort)
Stefano Alivernini¹, Barbara Tolusso ¹, Marco Gessi ², Maria Rita Gigante ¹, Luca Petricca ¹, Clara Di Mario ³, Simone Perniola ¹, Anna Laura Fedele ¹, Giusy Peluso ⁴, Laura Bui ², Annunziata Capacci ¹, Francesco Federico ², Gianfranco Ferraccioli ³ and Elisa Gremese ¹, ¹Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ²Division of Pathology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ³Institute of Rheumatology - Università Cattolica del Sacro Cuore, Rome, Italy, ⁴Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Italy, Italy
Background/Purpose: Ultrasound (US)-guided minimally-invasive Synovial Tissue (ST) biopsy is a well tolerated procedure for basic and translational studies on chronic inflammatory joint diseases as Rheumatoid…
Abstract Number: 2849 • 2019 ACR/ARP Annual Meeting
Radiographic Progression During a 10-Year Follow-Up : Results from the French Cohort ESPOIR
Joanna Kedra¹, David Hajage ², Alexandre Lafourcade ², Bernard Combe ³, Maxime Dougados ⁴ and Bruno Fautrel ⁵, ¹Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), UMR S1136, Paris France, Paris, France, ²Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, ³CHU Montpellier, Montpellier University, Montpellier, France, ⁴Cochin Hospital, Paris, France, ⁵Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France
Background/Purpose: In early arthritis, identification of patients at risk of developing joint damage is an important issue. In rheumatoid arthritis (RA), the rate of progression…
Abstract Number: 2850 • 2019 ACR/ARP Annual Meeting
Exploring Heterogeneity in Rheumatoid Arthritis: Outcomes up to 4 Years of Follow-Up in Patient Clusters Identified by Data-driven Analysis of the BRASS Registry
Jeffrey Curtis¹, Michael Weinblatt ², Kenneth Saag ¹, Vivian Bykerk ³, Christina Charles-Schoeman ⁴, Stefano Fiore ⁵, Gregory St John ⁶, Toshio Kimura ⁷, Shen Zheng ⁵, Clifton Bingham ⁸, Grace Wright ⁹, Martin Bergman ¹⁰, Kamala Nola ¹¹, Daniel Furst ⁴ and Nancy Shadick ², ¹University of Alabama at Birmingham, Birmingham, AL, ²Brigham and Women's Hospital, Boston, MA, ³Hospital for Special Surgery, New York City, NY, ⁴University of California, Los Angeles, CA, ⁵Sanofi Genzyme, Bridgewater, NJ, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁸Johns Hopkins University, Baltimore, MD, ⁹Private Practice, New York City, NY, ¹⁰Drexel University College of Medicine, Stockholm, Sweden, ¹¹Lipscomb University College of Pharmacy & Health Sciences, Nashville, TN
Background/Purpose: Patients with rheumatoid arthritis (RA) may share characteristics that relate to their future outcomes. We investigated clinical outcomes over a 4-year follow-up period in…
Abstract Number: 2851 • 2019 ACR/ARP Annual Meeting
Limiting Factors of Reaching ACR/EULAR Boolean Remission in Early RA Patients Treated According to Current Recommendations
Nina Sundlisater¹, Anna-Birgitte Aga ², Ulf Sundin ³, Hilde Hammer ¹, Till Uhlig ⁴, Tore Kvien ⁴, Espen Haavardsholm ⁴ and Siri Lillegraven ⁵, ¹Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, ²Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, ³Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway. University of Oslo, Oslo, Norway, Oslo, Oslo, Norway, ⁴Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁵Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway
Background/Purpose: Abrogation of inflammation is important to prevent irreversible joint damage and maximize health-related quality of life in early RA patients. The ACR/EULAR Boolean remission…
Abstract Number: 2852 • 2019 ACR/ARP Annual Meeting
Shared and Differing Risk Factors for PsA, Psoriasis, AS, and RA: A Series of Case-control Studies
Alexis Ogdie¹, Xingmei Wang ¹, Thorvardur J Love ², Telma Thrastardottir ³, Maureen Dubreuil ⁴ and Joel Gelfand ⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ³University of Iceland, Reykjavik, Iceland, ⁴Boston University School of Medicine, Boston, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: While a handful of clinical risk factors for the development of inflammatory diseases have been identified, to date, no studies have compared risk factors…
Abstract Number: 2853 • 2019 ACR/ARP Annual Meeting
The Pattern of Musculoskeletal Complaints in Patients with Suspected Psoriatic Arthritis and Their Correlation with Physical Examination and Ultrasound
Samantha Sarabia ¹, Chandra Farrer ², Jensen Yeung ³, Richard Cook ⁴, Ker-Ai Lee ⁵, Dana Jerome ³ and Lihi Eder⁶, ¹Faculty of Medicine, Queens University, Kingston, Canada, ²University of Toronto, Toronto, Canada, ³University of Toronto, Toronto, ⁴University of Waterloo, Waterloo, Canada, ⁵University of Waterloo, Waterloo, ⁶Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada
Background/Purpose: There is limited information about the constellation of musculoskeletal symptoms experienced by patients with early psoriatic arthritis (PsA). This study aims to describe the…
Abstract Number: 2854 • 2019 ACR/ARP Annual Meeting
Delay Between the Onset of Psoriasis and Arthritis in PsA Patients from the PsART International Cohort
Koray Tascilar¹, Sibel Zehra Aydin ², Servet Akar ³, Kenan Aksu ⁴, Sibel Bakirci ⁵, Ozun Bayindir ⁶, Meryem Can ⁷, Gozde Cetin ⁸, Muhammet Çınar ⁹, Ediz Dalkılıç ¹⁰, Atalay Dogru ¹¹, Abdulsamet Erden ¹², Emine Duygu Ersözlü ¹³, Şükran Erten ¹⁴, Timuçin Kaşifoğlu ¹⁵, Gezmiş Kimyon ¹⁶, Orhan Küçükşahin ¹⁷, Ahmet Omma ¹⁸, Cem Ozisler ¹⁹, Soner Senel ²⁰, Dilek Solmaz ²¹, Emine Figen Tarhan ²², Ilaria Tinazzi ²³, Sule Yavuz ²⁴, Sema Yılmaz ²⁵ and Umut Kalyoncu ²⁶, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, ²University of Ottawa Faculty of Medicine, Rheumatology,Ottawa Hospital Research Institute, 1967 Riverside Drive, Ottawa, ON, K1H 7W9, CANADA, Ottawa, Canada, ³Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ⁴Ege University, Department of Internal Medicine, Division of Rheumatology, Izmir, ⁵Antalya Education and Research Hospital, Antalya, Turkey, ⁶Ege University, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ⁷Marmara University, Division of Rheumatology, Istanbul, Turkey, Istanbul, Turkey, ⁸Kahramanmaras Sutcu Imam University, Department of Internal Medicine, Division of Rheumatology, Kahramanmaras, ⁹University of Medical Sciences, Ankara, Turkey, ¹⁰Uludağ University, Bursa, Turkey, ¹¹Suleyman Demirel University, Department of Internal Medicine, Division of Rheumatology, Isparta, Turkey, ¹²Hacettepe University, Ankara, Turkey, ¹³Adana State Hospital, Adana, Turkey, ¹⁴Yıldırım Beyazıt University, Ankara, Turkey, ¹⁵Eskişehir Osmangazi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Eskişehir, Turkey, ¹⁶Mustafa Kemal University, Hatay, Turkey, ¹⁷Liv Hospital, Ankara, Turkey, ¹⁸Ankara Numune Education and Research Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ¹⁹Diskapi Yildirim Beyazit Education and Research Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, ²⁰Division of Rheumatology, Erciyes University School of Medicine, Kayseri, Turkey, Kayseri, Turkey, ²¹Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ²²Mugla Sitki Kocman University, Department of Internal Medicine, Division of Rheumatology Mugla,, Mugla, Turkey, ²³Sacro Cuore Don Calabria Hospital, Unit of Rheumatology, Verona, Italy, ²⁴Uppsala University, Istanbul, Turkey, ²⁵Division of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, Konya, Turkey, ²⁶Hacettepe University Department of Rheumatology, Ankara, Turkey
Background/Purpose: Psoriatic arthritis is a heterogenous disorder not only with respect to patterns and components of musculoskeletal involvement but also with respect to types of…
Abstract Number: 2855 • 2019 ACR/ARP Annual Meeting
Clinically Relevant Patient Clusters Identified by Machine Learning Tools in a Large Database from the Secukinumab Psoriatic Arthritis Clinical Development Program
Iain McInnes¹, Matthias Kormaksson ², Effie Pournara ³, Gregory Ligozio ², Luminita Pricop ⁴, Peter Nash ⁵, Bruce Kirkham ⁶, Kristian Reich ⁷ and Christopher Ritchlin ⁸, ¹Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Novartis Pharmaceutical Corporation, New Jersey, NJ, ³Novartis Pharma AG, Basel, Basel-Stadt, Switzerland, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵University of Queensland, Brisbane, Queensland, Australia, ⁶Guy's & St Thomas' NHS Foundation Trust, London, England, United Kingdom, ⁷University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Skinflammation®, Hamburg, Germany; Dermatologikum Berlin, Berlin, Germany, Hamburg, Germany, ⁸Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY
Background/Purpose: Identifying clinically relevant patient phenotypes amidst the variability and heterogeneity of the clinical manifestations of psoriatic arthritis (PsA) is currently challenging. Using machine-learning (ML)…
Abstract Number: 2856 • 2019 ACR/ARP Annual Meeting
Drug Retention of Biological DMARDs Targeting IL-12/IL-23 or IL-17 versus TNF Inhibitors, After a First Line TNF Inhibitor, in Patients with Psoriatic Arthritis – an Analysis in the Swiss SCQM Register
Burkhard Moeller¹, Eleftherios Papagiannoulis ², Lisa Christ ³, Adrian Ciurea ⁴, Thomas Hugle ⁵, Ruediger B. Mueller ⁶, Michael J. Nissen ⁷, Almut Scherer ⁸, Godehard Scholz ³, Peter M. Villiger ¹ and Nikhil Yawalkar ³, ¹University Hospital Bern, Bern, Switzerland, ²SCQM Zurich, Zurich, Switzerland, ³Inselspital-University Hospital Bern, Bern, Switzerland, ⁴University Hospital Zürich, Zürich, Switzerland, ⁵University Hospital Lausanne, Lausanne, Switzerland, ⁶Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Aargau, Switzerland, ⁷University Hospital Geneva, Geneva, Switzerland, ⁸SCQM Foundation, Zürich, Switzerland
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) were the first approved biological disease modifying antirheumatic drugs (bDMARDs) for psoriatic arthritis (PsA). IL-12/23 and IL-17-specific antibodies provide…
Abstract Number: 2857 • 2019 ACR/ARP Annual Meeting
Decision Tree Analysis to Identify Inflammatory Arthritis Patient Subgroups with Different Levels of Treatment Persistence with First-Line Subcutaneous TNF-alpha Inhibitors
Emma Hernlund ¹, Johan Klint ¹, Axel Svedbom ¹, Johan Dalén ¹, Christopher Black ² and Amy Puenpatom², ¹ICON plc, Stockholm, Sweden, Stockholm, Sweden, ²Merck & Co., Inc., Kenilworth, NJ, United States, Kenilworth, NJ
Background/Purpose: The advent of biologic medications, such as subcutaneous TNF-alpha inhibitors (SC-TNFi), has transformed the management of inflammatory arthritis (IA) during the last decades. However,…
Abstract Number: 2858 • 2019 ACR/ARP Annual Meeting
The Role of Bradykinin Receptor B1 and Its New Ligand Soluble CD13 in Rheumatoid Arthritis and Inflammatory Arthritis Mouse Model
Chenyang Lu ¹, Phillip Campbell ¹, Jonatan Hervoso ², Stephanie Rasmussen ², Wenyi Fu ², Jeffrey Ruth ², David Fox ³ and M Amin⁴, ¹the University of Michigan, Ann Arbor, MI, ²the University of Michigan, Ann Arbor, ³University of Michigan, Ann Arbor, ⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory disorder characterized by synovial hyperplasia, inflammatory cell infiltration and pannus formation. We have shown that soluble CD13 (sCD13)…
Abstract Number: 2859 • 2019 ACR/ARP Annual Meeting
Citrulline Reactive B Cells Are Present in the Lungs of Early Untreated RA
Vijay Joshua¹, Malena Loberg-Haarhaus ¹, Heidi Wähämaa ², Aase Hensvold ², Khaled Amara ¹, Lena Israelsson ¹, Ragnhild Stålesen ¹, Magnus Sköld ³, Johan Grunewald ³, Caroline Grönwall ¹, Vivianne Malmström ¹ and Anca Catrina ⁴, ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden, ²Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, ³Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden., Stockholm, Sweden, ⁴Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Structural changes, increased tissue citrullination, signs of local inflammation and anti-citrullinated protein autoantibodies (ACPA) are present in the pulmonary compartment of early untreated seropositive…
Abstract Number: 2860 • 2019 ACR/ARP Annual Meeting
Perturbation of the Human Gut Microbiome by Methotrexate Contributes to the Resolution of Inflammation and Autoimmune Disease
Renuka Nayak¹, Margaret Alexander ¹, Kye Stapleton-Grey ², Carles Ubeda ³, Jose Scher ⁴ and Peter Turnbaugh ¹, ¹UCSF, San Francisco, ²Carnegie Mellon, Pittsburg, ³Centro Superior de Investigación en Salud Pública - FISABIO, Valencia, Spain, ⁴Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY
Background/Purpose: The trillions of microorganisms (microbiota) found within the human gut play a critical role in shaping the immune system, yet these complex microbial communities…
Abstract Number: 2861 • 2019 ACR/ARP Annual Meeting
Lung-Related Factors Are Associated with Transitions from Systemic Anti-CCP Antibody Positivity to Classified RA
Ashley Visser ¹, Marie Feser ², Chelsie Fleischer ³, Laura Lenis-Charry ¹, Justin August ¹, Elizabeth Bemis ⁴, Jill Norris ⁵, V. Michael Holers ⁶, Kevin Deane ² and M. Kristen Demoruelle⁷, ¹University of Colorado Denver, Aurora, ²University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO USA, Aurora, ⁴University of Colorado Denver, School of Public Health, Aurora, CO USA, Aurora, ⁵Colorado School of Public Health, Aurora, ⁶University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁷University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora
Background/Purpose: Systemic autoimmunity associated with RA precedes the onset of inflammatory arthritis (IA) by several years. In particular, the presence of systemic anti-cyclic citrullinated peptide…
Abstract Number: 2862 • 2019 ACR/ARP Annual Meeting
Hypoxia Resistant Pathogenic B Cells Accumulate in the RA Synovial Tissue in a CXCR3 Dependent Manner
Achilleas Floudas¹, Candice Low ², Monika Biniecka ³, Kieran Murray ², Ronan Mullan ⁴, Douglas Veale ⁵ and Ursula Fearon ⁶, ¹Trinity Biomedical Sciences Institu, DUBLIN, Ireland, ²Saint Vincent's University Hospital, Dublin, Ireland, ³Molecular Rheumatology, Trinity Biomedical Sciences Institute, DUBLIN, Ireland, ⁴Dept of Rheumatology, Tallaght University Hospital, TCD, Dublin, Ireland, ⁵EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland, ⁶Molecular Rheumatology, Trinity Biomedical Sciences Institute, TCD, Dublin, Ireland
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease of unknown and complex aetiology with severe detrimental effects for the patient’s quality of life.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].